CXCL10 also demonstrated a certain level of accuracy in predicting the response of BLCA patients to immune therapy (IMvigor210 cohort: Lauss, Kim, and Hwang cohort) (Fig. 6C). Here, CXCL10 is linked to bladder transitional cell carcinoma.